Compare CXE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXE | CRDF |
|---|---|---|
| Founded | 1989 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.1M | 130.7M |
| IPO Year | N/A | 2012 |
| Metric | CXE | CRDF |
|---|---|---|
| Price | $3.79 | $1.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $9.63 |
| AVG Volume (30 Days) | 72.4K | ★ 678.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.36% | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | ★ 0.07 | N/A |
| Revenue | N/A | ★ $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $54.43 | ★ N/A |
| Revenue Growth | N/A | ★ 49.61 |
| 52 Week Low | $3.38 | $1.48 |
| 52 Week High | $3.88 | $4.56 |
| Indicator | CXE | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 48.86 | 54.12 |
| Support Level | $3.66 | $1.51 |
| Resistance Level | N/A | $2.05 |
| Average True Range (ATR) | 0.05 | 0.13 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 33.33 | 89.11 |
Mfs High Income Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company's investment portfolio has shares from the industry Healthcare, Airports, and Secondary Schools.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.